Esprit BTK Everolimus Eluting Resorbable Scaffold System
ABBOTT MEDICAL · Decision date Sep 24, 2026
What did the FDA approve?
FDA recorded an approval decision dated 2026-09-24 for P230036/S020, a Special (Immediate Track) PMA supplement to Abbott Medical's Esprit BTK Everolimus Eluting Resorbable Scaffold System. The supplement reason is listed as a process change affecting manufacturer, sterilizer, packager or supplier. The recorded scope is the addition of in-process scaffold dimensional inspections for the Esprit BTK LL System, a manufacturing step rather than a change to the device's clinical use.
The underlying product is categorized as an absorbable infrapopliteal scaffold under product code NXW, in the cardiovascular specialty. This action amends the existing P230036 application; it is not a new approval of the whole system, and the source record does not describe the original approval date, indications, or the dimensional specifications and acceptance criteria tied to the added inspections. No supporting documents were included, so the inspection methods and validation data remain unknown.
FDA approval order statement
addition of in-process scaffold dimensional inspections for the Esprit BTK LL System
- Regulatory pathway
- PMA supplement
- Supplement type
- Special (Immediate Track)
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 24, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P230036/S020
- Regulatory pathway
- PMA supplement
- Applicant
- ABBOTT MEDICAL
- Product code
- NXW
- Decision code
- APPR
- Decision date
- Sep 24, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Scaffold, infrapopliteal, absorbable.
- Applicant
- Abbott Medical
- Product code
- NXW
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P230036. Subsequent supplements may change the device or its indications.
FDA decision timeline
P230036 · Original PMA
Esprit BTK Everolimus Eluting Resorbable Scaffold System
P230036/S020 received
Application receipt date recorded by FDA.
P230036/S020 · FDA decision
Special (Immediate Track)
Timeline entries are records held by MedtechLedger for P230036. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230036
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT MEDICAL | PMA approval | Apr 26, 2024 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Medical
- Headquarters
- Not reported
- Brand website
- abbott.com
- FDA applicant address
- 3200 Lakeside Dr., Santa Clara, CA, 95054
Sources and methodology
- Original FDA record: P230036/S020
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records